L'intérêt à découvert pour ACADIA Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de ACADIA Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Rapport sur les intérêts à découvert

ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals Inc

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports and Outdoors Inc

Academy Veteran Impact ETF

ACADIA ENERGY CORP by Acadia Energy Corporation

Acadia Energy Corp

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Realty Trust

Acadian Asset Management Inc. Common Stock

Acadian Asset Management Inc

ACADIAN TIMBER CORP ORD by Acadian Timber Corp

Acadian Timber Corp

Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Perform and raises the price target from $19 to $22.

News

Price Target

Analyst Ratings

ACAD

Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $22

JMP Securities analyst Jason Butler reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Market Outperform and maintains $37 price target.

Reiteration

JMP Securities Reiterates Market Outperform on ACADIA Pharmaceuticals, Maintains $37 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $32 price target.

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $30 price target.

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $30 Price Target

In the preceding three months, 13 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.46, a high estimate of $38.00, and a low estimate of $22.00. This current average has increased by 17.46% from the previous average price target of $24.23. 
<img src="https://www.benzinga.com/files/images/story/2025/1750708877_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of ACADIA Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Tessa Romero</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ACADIA Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into ACADIA Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>Get to Know ACADIA Pharmaceuticals Better</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>Financial Insights: ACADIA Pharmaceuticals</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: ACADIA Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 18.7%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: ACADIA Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 7.77%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.64%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $26 to $38.

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $38

- Composition of matter patent affirmed, provides protection into 2030
- Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038
Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID&#xAE; (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.
In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date."

Biotech

Legal

General

Acadia Wins Appeals Court Affirmation Of NUPLAZID Composition Of Matter Patent Valid Through 2030, Strengthening IP Protection Alongside Recent Formulation Patent Ruling Extending To 2038

In May, the U.S. District Court for the District of Delaware ruled in favor of ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia&#8217;s drug for the treatment of <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Parkinson&#8217;s Disease Psychosis</a>.
In order, the court ruled in favor of Acadia on infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New <a href="https://www.benzinga.com/pressreleases/25/05/b45474227/delaware-district-court-rules-in-favor-of-acadia-in-nuplazid-pimavanserin-formulation-patent-litig" target="_blank" rel="noreferrer noopener">Drug Application) filers</a>.
&#8220;We are very pleased with today&#8217;s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,&#8221; said CEO Catherine Owen Adams.
JPMorgan sees the ruling as &#8220;as a clear positive.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/05/45476079/acadia-pharmaceuticals-acad-stock-explodes-26-after-patent-court-victory" rel="noreferrer noopener">Acadia Pharmaceuticals (ACAD) Stock Explodes 26% After Patent Court Victory</a>
Analyst Tessa T Romero writes, &#8220;We believe it is logical to assume the parties would appeal the ruling, a process that could take ~1-2 years from start to finish.&#8221;
JPMorgan on Friday increased the price target from $26 to $30, reiterating <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings" target="_blank" rel="noreferrer noopener">the Overweight rating</a>.
The analyst also notes the appeal in the composition of matter (COM) patent litigation at the U.S. Court of Appeals for the Federal Circuit is scheduled for June 6. The patent at issue is the ‘740 COM patent, which covers pimavanserin and salts thereof into 2030, including a patent term extension approved by the U.S. Patent and Trademark Office.
The JPMorgan analyst is confident that the U.S. Court of Appeals will favor Acadia on the ‘740 patent case. The analyst points to three reasons:
<ul class="wp-block-list">
<li>In December 2023, a lower court ruled in Acadia&#8217;s favor, confirming the patent&#8217;s validity.</li>
<li>A similar case involving Allergan also ended positively, which supports Acadia&#8217;s position.</li>
<li>Legal experts consulted by JPMorgan believe there&#8217;s a 95% chance the ruling will go Acadia&#8217;s way.</li>
</ul>
The increased price target is based on the analyst&#8217;s conviction around a favorable outcome from the U.S. Court of Appeals for the Federal Circuit on the ‘740 patent.
Analyst Romero extended Nuplazid LOE assumption to 2038 from 2030 and, at the same time, accounted for potential headwinds from price negotiations under the IRA in the outer years as well as potential competitive threats from certain generic entrants, which could become available following the expiry of Nuplazid&#8217;s COM patent in 2030.
ACAD Price Action: ACADIA stock is up 2.18% at $21.81 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/06/45797712/moderna-beats-alnylam-appeal-in-covid-vaccine-patent-case" target="_blank" rel="noreferrer noopener">Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case</a></li>
</ul>
Photo: Piotr Swat via Shutterstock

Analyst Color

Large Cap

Health Care

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Overweight and raises the price target from $26 to $30.

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $30

Across the recent three months, 11 analysts have shared their insights on ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.45, with a high estimate of $35.00 and a low estimate of $22.00. Witnessing a positive shift, the current average has risen by 14.81% from the previous average price target of $23.91.
<img src="https://www.benzinga.com/files/images/story/2025/1749146492_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of ACADIA Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of ACADIA Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>Get to Know ACADIA Pharmaceuticals Better</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>ACADIA Pharmaceuticals's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 18.7% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.77%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 2.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.07, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Neutral and raises the price target from $18 to $23.

B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $23

Deutsche Bank analyst David Hoang upgrades ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) from Hold to Buy and raises the price target from $20 to $35.

Upgrades

Deutsche Bank Upgrades ACADIA Pharmaceuticals to Buy, Raises Price Target to $35

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Equal-Weight and raises the price target from $20 to $24.

Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $24

Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Neutral and raises the price target from $20 to $23.

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $23

Baird analyst Joel Beatty maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $28 to $31.

Baird Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $31

RBC Capital analyst Gregory Renza reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and maintains $26 price target.

RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $26 Price Target

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $24 to $28.

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $28

ACADIA Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) announced a favorable <a href="https://www.benzinga.com/quote/ACAD">court ruling on Friday</a>.
The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia&#8217;s ‘721 formulation patent for NUPLAZID (pimavanserin), a treatment for Parkinson's Disease Psychosis.
The decision protects the 34 mg capsule formulation from generic competition until 2038, blocking challenges from Aurobindo Pharma and other generic drugmakers.
&#8220;We are very pleased with today&#8217;s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,&#8221; said Catherine Owen Adams, Chief Executive Officer. &#8220;This result highlights Acadia&#8217;s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs.&#8221;
ACADIA Pharmaceuticals shares gained 26.5% to close at $22.26 on Friday.
These analysts made changes to their price targets on ACADIA Pharmaceuticals following the announcement.
<ul class="wp-block-list">
<li>Needham analyst Ami Fadia maintained ACADIA Pharmaceuticals with a Buy and raised the price target from $27 to $30.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein maintained the stock with a Buy and boosted the price target from $27 to $32.</li>
</ul>
Considering buying ACAD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="638" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png" alt="" class="wp-image-919746" style="width:687px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-1024x638.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-300x187.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230-768x479.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19082408/image-230.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

In the preceding three months, 8 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $26.88, a high estimate of $32.00, and a low estimate of $20.00. Witnessing a positive shift, the current average has risen by 2.4% from the previous average price target of $26.25.
<img src="https://www.benzinga.com/files/images/story/2025/1747656047_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of ACADIA Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ACADIA Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>About ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
<h3>A Deep Dive into ACADIA Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 18.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.64%, the company showcases effective utilization of assets.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For ACADIA Pharmaceuticals

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) price target from $27 to $30. Needham analyst Ami Fadia maintained a Buy rating. ACADIA Pharmaceuticals shares closed at $22.26 on Friday. <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from $40.8 to $29. Jefferies analyst Giacomo Romeo downgraded the stock from Buy to Hold. BP shares closed at $29.76 on Friday. <a href="https://www.benzinga.com/quote/BP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan boosted Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) price target from $5 to $6. JP Morgan analyst Tien-Tsin Huang upgraded the stock from Neutral to Overweight. Marqeta shares closed at $5.04 on Friday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $1,150 to $1,220. JP Morgan analyst Doug Anmuth downgraded the stock from Overweight to Neutral. Netflix shares closed at $1,191.53 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from $131 to $166. Barclays analyst Seth Sigman upgraded the stock from Underweight to Equal-Weight. Williams-Sonoma shares closed at $173.84 on Friday. <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) price target from $27 to $32. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. ACADIA Pharmaceuticals shares settled at $22.26 on Friday. <a href="https://www.benzinga.com/quote/ACAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital raised Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) price target from $430 to $510. Loop Capital analyst Alan Gould upgraded the stock from Hold to Buy. Charter Communications shares closed at $427.25 on Friday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup cut Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) price target from $25 to $19. Citigroup analyst Scott Gruber downgraded the stock from Buy to Neutral. Helmerich &amp; Payne shares closed at $17.80 on Friday.  <a href="https://www.benzinga.com/quote/HP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased the price target for Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) from $46 to $66. UBS analyst Thomas Wadewitz upgraded the stock from Neutral to Buy. Delta Air Lines shares settled at $50.92 on Friday. <a href="https://www.benzinga.com/quote/DAL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) price target from $55 to $60. UBS analyst Manav Gupta upgraded the stock from Neutral to Buy. Archer-Daniels-Midland shares closed at $50.13 on Friday. <a href="https://www.benzinga.com/quote/adm/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-1024x598.png" alt="" class="wp-image-919670" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19075050/image-226.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45490061/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-6">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

CHTR

NFLX

Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday

Press Releases

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Comments

ACADIA Pharmaceuticals

Intérêt court

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL